The accompanying notes are an integral part of
these unaudited condensed financial statements.
The accompanying notes are an integral part of
these unaudited condensed financial statements.
The accompanying notes are an integral part of
these unaudited condensed financial statements.
The accompanying notes are an integral part of
these unaudited condensed financial statements.
The accompanying notes are an integral part of
these unaudited condensed financial statements.
Notes to Unaudited Condensed Financial Statements
| 1. | DESCRIPTION OF BUSINESS |
Organization
Alzamend Neuro, Inc. (the
“Company” or “Alzamend”), is an early clinical-stage biopharmaceutical company focused on developing novel products
for the treatment of neurodegenerative diseases and psychiatric disorders. The Company’s primary focus is Alzheimer’s disease.
With two current and future product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as
possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”):
(i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001, through
two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the “Licensor”);
and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability
of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide
license from the same Licensor.
The Company is devoting substantially
all its efforts towards research and development of its Technology and raising capital. The Company has not generated any product revenue
to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par
value $0.0001 per share (“Common Stock”). The Company expects to continue to incur net losses in the foreseeable future.
| 2. | LIQUIDITY AND GOING CONCERN |
The accompanying condensed
financial statements have been prepared on the basis that the Company will continue as a going concern. As of July 31, 2022, the Company
had cash of $11.5 million and an accumulated deficit of $32.2 million. The Company incurred losses for the three months ended July 31,
2022 totaling $3.0 million. Historically, the Company has financed its operations principally through issuances of equity and debt instruments.
The Company expects to continue to incur losses for the foreseeable
future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development
and commercial operations. However, based on the Company’s current business plan, management believes that the Company’s cash
at July 31, 2022 is sufficient to meet the Company’s anticipated cash requirements during the twelve-month period subsequent to
the issuance of the financial statements included in this Quarterly Report.
| 3. | SIGNIFICANT ACCOUNTING POLICIES |
Basis of Presentation
The accompanying condensed
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim
reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited
financial statements and notes thereto contained in the Company’s Report on Form 10-K for the year ended April 30, 2022, filed with
the SEC on July 19, 2022. In the opinion of management, the accompanying condensed interim financial statements include all adjustments
necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily
indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that
would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported
in the Company’s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2022 has been derived
from the audited balance sheet at April 30, 2022 contained in such Form 10-K.
Accounting Estimates
The preparation of financial
statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates
include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all
highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of July 31, 2022
and April 30, 2022, the Company had no cash equivalents.
Fair Value of Financial
Instruments
Financial Accounting Standards
Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, defines fair value
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques
used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy
is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last
is considered unobservable:
Level 1: Quoted prices in
active markets for identical assets or liabilities.
Level 2: Inputs other than
Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in
markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the
full term of the assets or liabilities.
Level 3 assumptions: Unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including
liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.
The fair values of warrants
are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value
of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market
capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants
and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’
contractual life.
Property and Equipment,
Net
Property and equipment are
stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life
of five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.
Research and Development
Expenses
Research and development costs
are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid
to other entities that conduct certain research and development activities on behalf of the Company.
The Company has acquired and
may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire
license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense
provided that there is no alternative future use of the rights in other research and development projects.
Stock-Based Compensation
The Company recognizes stock-based
compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes
option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management
evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance
conditions as of the reporting date.
The Company recognizes stock-based
compensation expense for restricted stocks on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company’s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.
The Black-Scholes option pricing
model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions
involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the
Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially different.
Warrants
The Company accounts for stock
warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480, Distinguishing Liabilities
from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”), depending
on the specific terms of the warrant agreement.
Loss per Common Share
The Company utilizes FASB
ASC 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average
number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is
increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued
and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible
preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then
shared in the earnings of the entity.
Since the effects of outstanding
options, warrants, convertible preferred stock and convertible notes are anti-dilutive in the periods presented, shares of Common Stock
underlying these instruments have been excluded from the computation of loss per common share.
The following sets forth the
number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have
been excluded from the computation of loss per common share:
| |
For the Three Months Ended July 31, | |
| |
2022 | | |
2021 | |
Series A convertible preferred stock | |
| - | | |
| 15,000,000 | |
Stock options (1) | |
| 18,600,000 | | |
| 17,500,000 | |
Warrants | |
| 10,149,788 | | |
| 8,830,785 | |
Convertible notes | |
| - | | |
| 232,049 | |
| |
| 28,749,788 | | |
| 41,562,834 | |
(1)
The Company has excluded
2,000,000
stock options, with
an exercise price of $0.0004,
from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares
issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.
Recent Accounting Standards
From time to time, new accounting
pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact
of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position
or results of operations upon adoption.
The Company has considered
all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its
financial statements.
| 4. | NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY |
On April 30, 2019, the Company
and Ault Life Sciences Fund, LLC (“ALSF”) entered into a securities purchase agreement for the purchase of 10,000,000 shares
of Common Stock for a total purchase price of $15,000,000, or $1.50 per share with 5,000,000 warrants with a 5-year life and an exercise
price of $3.00 per share and vesting upon issuance. The total purchase price of $15,000,000 was in the form of a non-interest bearing
note receivable with a 12-month term from ALSF, a related party. In November 2019, the term of the note receivable was extended to December
31, 2021, and in May 2021, the term of the note receivable was extended to December 31, 2023. The note is secured by a pledge of the purchased
shares. As the note receivable from ALSF is related to the issuance of Common Stock, it is recorded as an offset to additional paid-in
capital. At July 31, 2022 and April 30, 2022, the outstanding balance of the note receivable was $14,883,295. ALSF is wholly owned by
Ault Life Sciences, Inc. (“ALSI”). ALSI is majority owned by Ault & Company, Inc. (“Ault & Co.”). Messrs.
Horne and Nisser, directors of the Company, are also directors of Ault & Co.
5. | | PREPAID EXPENSES AND OTHER CURRENT ASSETS |
Prepaid expenses and other
current assets are as follows:
| |
July 31, 2022 | | |
April 30, 2022 | |
Prepaid consulting fees | |
$ | 116,667 | | |
$ | 186,667 | |
Prepaid insurance | |
| 451,885 | | |
| 155,880 | |
Other prepaid expenses | |
| 9,577 | | |
| 7,176 | |
Other receivables | |
| 9,413 | | |
| - | |
Total prepaid expenses and other current assets | |
$ | 587,542 | | |
$ | 349,723 | |
On June 16, 2022, the
Company purchased D&O insurance for 12 months in the amount of $492,000. Prepaid insurance at July 31, 2022 represented the unamortized
portion of annual premium paid for this policy of $452,000. At July 31, 2022, prepaid consulting fees of $117,000 consisted of payments
to Spartan Capital Securities, LLC (“Spartan Capital”).
| 6. | STOCK-BASED COMPENSATION |
2016 Stock Incentive
Plan
On April 30, 2016, the Company’s
stockholders approved the Company’s 2016 Stock Incentive Plan (the “Plan”). The Plan provides for the issuance of a
maximum of 12,500,000 shares of Common Stock to be offered to the Company’s directors, officers, employees, and consultants. On
March 1, 2019, the Company’s stockholders approved an additional 7,500,000 shares to be available for issuance under the Plan. Options
granted under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant
and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and 10 years from
the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant.
2021 Stock Incentive
Plan
In February 2021, the Company’s
board of directors (the “Board”) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan
(the “2021 Plan”). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory),
(2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation.
Stock Subject to the 2021
Plan. The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 10,000,000 shares, which number
will be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as
otherwise provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution
or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company
acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized
for grant under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer
under the 2021 Plan.
All options that the Company
grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company
has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the date of issuance of these options,
there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined
based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other
entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an
equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options
used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because the Company settles
these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments.
A summary of stock option
activity for the three months ended July 31, 2022 is presented below:
| |
| | | |
Outstanding Options | |
| |
| Shares Available for Grant | | |
| Number of Shares | | |
| Weighted Average Exercise Price | | |
| Weighted Average Remaining Contractual Life (years) | | |
| Aggregate Intrinsic Value | |
Balance at April 30, 2022 | |
| 8,800,000 | | |
| 15,700,000 | | |
$ | 1.20 | | |
| 6.10 | | |
$ | 2,219,700 | |
Options granted | |
| - | | |
| - | | |
$ | - | | |
| - | | |
| | |
Options exercised | |
| - | | |
| - | | |
$ | - | | |
| - | | |
| | |
Options expired | |
| - | | |
| (1,100,000 | ) | |
$ | 1.00 | | |
| - | | |
| | |
Balance at July 31, 2022 | |
| 8,800,000 | | |
| 14,600,000 | | |
$ | 1.22 | | |
| 5.79 | | |
$ | 1,777,200 | |
Options vested and expected to vest at July 31, 2022 | | |
| 13,700,000 | | |
$ | 1.23 | | |
| 6.36 | | |
$ | 1,777,200 | |
Options exercisable at July 31, 2022 | |
| | | |
| 11,514,479 | | |
$ | 1.07 | | |
| 6.03 | | |
$ | 1,777,200 | |
The aggregate intrinsic value
in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective
date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised
their options.
Stock Options Granted to Employees and Consultants
The estimated fair value of
stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes
option-pricing model using the following assumptions:
| |
For the Three Months Ended July 31, |
| |
2022 | | |
2021 |
Expected term (in years) | |
- | | |
2.50 – 5.00 |
Volatility | |
- | | |
86.31% |
Risk-free interest rate | |
- | | |
1.01%-1.07% |
Dividend yield | |
- | | |
0.0% |
Expected Term: The
expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method
(based on the mid-point between the vesting date and the end of the contractual term).
Expected Volatility: The
Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry
that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common
Stock at July 31, 2022. The Company will continue to apply this process until a sufficient amount of historical information regarding
the volatility of its own stock price becomes available.
Risk-Free Interest Rate: The
Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities
with similar maturities as of the date of the grant.
Expected Dividend: The
Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.
Stock-based compensation to
employees and consultants from stock option grants for the three months ended July 31, 2022 and 2021 were $867,000 and $740,000, respectively.
Performance Contingent
Stock Options Granted to Employee
In November 2018, the Board
granted 2,000,000 performance-contingent options under the Plan to the Chief Executive Officer. These options have an exercise price of
$1.00 per share.
These options have two separate
performance triggers for vesting based upon the therapies achieving certain Food and Drug Administration (“FDA”) approval
milestones within a specified timeframe. By definition, the performance condition in these options can only be achieved after the performance
condition of FDA approval has been achieved. As such, the requisite service period is based on the estimated period over which the market
condition can be achieved. When a performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based
compensation expense commences. In the event any of the milestones are not achieved by the specified timelines, such vesting award will
terminate and no longer be exercisable with respect to that portion of the shares. The maximum potential expense associated with the performance-contingent
awards is $1.2 million of general and administrative expense if all of the performance conditions are achieved as stated in the option
agreement. Due to the significant risks and uncertainties associated with FDA approvals, as of July 31, 2022, the Company believes that
the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for
these awards.
On November 26, 2019, the
Board granted 4,250,000 performance- and market-contingent awards to certain key employees and a director. These grants were made outside
of the Plan. These awards have an exercise price of $1.50 per share. These awards have multiple separate market triggers for vesting based
upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading
days later than 180 days after the Company’s initial public offering (“IPO”) for its Common Stock, or (ii) stepped target
prices for a change in control transaction. The target prices range from $15 per share to $40 per share. In the event any of the stock
price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%. Due to the
significant risks and uncertainties associated with achieving the market-contingent awards, as of July 31, 2022, the Company believes
that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized
for these awards.
Performance Contingent
Stock Options Granted to TAMM Net
On March 23, 2021, the Company
issued performance-based stock options to the certain team members at TAMM Net, Inc. to purchase an aggregate of 450,000 shares of Common
Stock at a per share exercise price of $1.50 per share, of which 50% vest upon the completion of Phase I of AL001 by March 31, 2022, and
the remaining 50% vest upon completion of Phase I of AL002 by December 31, 2022.
The performance goal of completing
Phase I of AL001 was achieved on March 22, 2022, and the Company recognized stock compensation related to the completion of Phase I of
AL001 over the implied service period to complete this milestone. Due to the significant risks and uncertainties associated with achieving
the completion of Phase I for AL002, as of July 31, 2022, the Company believes that the achievement of the requisite performance conditions
is not probable and, as a result, no compensation cost has been recognized for these awards related to AL002.
Performance Contingent
Stock Options Granted to Consultants
On October 14, 2021, the Company
issued performance-based stock options to two consultants to purchase an aggregate of 200,000 shares of Common Stock with an exercise
price of $2.42 per share, of which 50,000 vest upon completion of each of the Phase II clinical trials of AL001 for a Bipolar indication,
AL001 for a PTSD indication, AL001 for a depression indication and AL002 for an Alzheimer’s indication.
As of July 31, 2022, the Company
believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been
recognized for these awards related to Phase II of AL001 and AL002.
Stock-Based Compensation
Expense
The Company’s results
of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised
as follows:
| |
For the Three Months Ended July 31, | |
| |
2022 | | |
2021 | |
Research and development | |
$ | - | | |
$ | 141,917 | |
General and administrative | |
| 867,338 | | |
| 597,705 | |
Total | |
$ | 867,338 | | |
$ | 739,622 | |
As of July 31, 2022, total
unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $3.7 million.
The weighted-average period over which such stock-based compensation expense will be recognized is approximately 2.2 years.
The following table summarizes
information about Common Stock warrants outstanding and exercisable at July 31, 2022:
Outstanding |
|
|
Exercisable |
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average |
|
|
Weighted |
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
Remaining |
|
|
Average |
|
|
|
|
|
Average |
|
Exercise |
|
|
Number |
|
|
Contractual |
|
|
Exercise |
|
|
Number |
|
|
Exercise |
|
Price |
|
|
Outstanding |
|
|
Life (years) |
|
|
Price |
|
|
Exercisable |
|
|
Price |
|
$ |
1.00 |
|
|
|
500,000 |
|
|
|
1.6 |
|
|
$ |
1.00 |
|
|
|
500,000 |
|
|
$ |
1.00 |
|
$ |
1.75 |
|
|
|
161,342 |
|
|
|
2.3 |
|
|
$ |
1.75 |
|
|
|
161,342 |
|
|
$ |
1.75 |
|
$ |
3.00 |
|
|
|
9,427,196 |
|
|
|
2.7 |
|
|
$ |
3.00 |
|
|
|
9,427,196 |
|
|
$ |
3.00 |
|
$ |
6.25 |
|
|
|
61,250 |
|
|
|
3.9 |
|
|
$ |
6.25 |
|
|
|
61,250 |
|
|
$ |
6.25 |
|
|
$1.00 - $6.25 |
|
|
|
10,149,788 |
|
|
|
2.6 |
|
|
$ |
2.90 |
|
|
|
10,149,788 |
|
|
$ |
2.90 |
|
The estimated fair value of warrants granted during
the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:
| |
For the Three Months Ended July 31, |
| |
2022 | |
2021 |
Expected term (in years) | |
- | |
5.00 |
Volatility | |
- | |
103.70% |
Risk-free interest rate | |
- | |
0.27% - 0.28% |
Dividend yield | |
- | |
0.0% |
Expected Term: The
expected term represents the period that the warrants granted are expected to be outstanding.
Expected Volatility: The
Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry
that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common
Stock at July 31, 2021. The Company will continue to apply this process until a sufficient amount of historical information regarding
the volatility of its own stock price becomes available.
Risk-Free Interest Rate: The
Company based the risk-free interest rate over the expected term of the warrants based on the constant maturity rate of U.S. Treasury
securities with similar maturities as of the date of the grant.
Expected Dividend: The
Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.
| 8. | OTHER RELATED PARTY TRANSACTIONS |
In March 2021, the Company
entered into a securities purchase agreement with Digital Power Lending, LLC (“DPL”) pursuant to which the Company sold an
aggregate of 6,666,667 shares of Common Stock for an aggregate of $10 million, or $1.50 per share, which sales were made in tranches.
On March 9, 2021, DPL paid $4 million, less the $1.8 million in prior advances and the surrender for cancellation of a $50,000 convertible
promissory note held by BitNile Holdings, Inc. (“BitNile”), the parent company of DPL, for an aggregate of 2,666,667 shares
of Common Stock. Under the terms of the securities purchase agreement, DPL (i) purchased an additional 1,333,333 shares of Common Stock
upon approval of the IND for Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares
of Common Stock upon the completion of Phase IA clinical trials for AL001 for a purchase price of $4 million. The Company issued to DPL
warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a
period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional
$10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of
the date of this Quarterly Report.
| 9. | COMMITMENTS AND CONTINGENCIES |
Contractual Obligations
On May 1, 2016, the Company
entered into a Standard Exclusive License Agreement for AL002 with Sublicensing Terms with Licensor, pursuant to which Licensor granted
the Company a royalty bearing exclusive worldwide license limited to the field of Alzheimer’s Immunotherapy and Diagnostics, under
United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use,” filed April 7, 2009 and granted
May 29, 2012.
There
are certain initial license fees and milestone payments required to be paid by the Company to the Licensor pursuant to the terms of license
agreements. The license agreements for AL002 require the Company to pay royalty payments of 4% on net sales of products developed
from the licensed technology for AL002 while the license agreements for AL001 require that the Company pay combined royalty payments of 4.5%
on net sales of products developed from the licensed technology for AL001. The Company has already paid an initial license fee of
$200,000 for AL002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of AL002, the Licensor
received 3,601,809 shares of common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received
2,227,923 shares of common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year
thereafter, for the life of the agreement. Minimum royalties for AL002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every
year thereafter, for the life of the respective agreement. Additionally, the Company is required to pay milestone payments on the
due dates to the Licensor for the license of the AL001 technologies and for the AL002 technology, as follows:
Original
AL001 License:
Payment |
|
Due Date |
|
Event |
$ |
50,000 |
* |
Completed September 2019 |
|
Pre-IND meeting |
|
|
|
|
|
|
$ |
65,000 |
* |
Completed June 2021 |
|
IND application filing |
|
|
|
|
|
|
$ |
190,000 |
* |
Completed December 2021 |
|
Upon first dosing of patient in a clinical trial |
|
|
|
|
|
|
$ |
500,000 |
* |
Completed March 2022 |
|
Upon Completion of first clinical trial |
|
|
|
|
|
|
$ |
1,250,000 |
|
12 months from completion of the first Phase II clinical trial |
|
Upon first patient treated in a Phase III clinical trial |
|
|
|
|
|
|
$ |
10,000,000 |
|
8 years from the effective date of the agreement |
|
Upon FDA approval |
* |
|
Milestone met and completed |
AL002
License:
Payment |
|
Due Date |
|
Event |
$ |
50,000 |
* |
Completed January 2022 |
|
Upon IND application filing |
|
|
|
|
|
|
$ |
50,000 |
|
12 months from IND application filing date |
|
Upon first dosing of patient in first Phase I clinical trial |
|
|
|
|
|
|
$ |
175,000 |
|
12 months from first patient dosed in Phase I |
|
Upon completion of first Phase I clinical trial |
|
|
|
|
|
|
$ |
500,000 |
|
24 months from completion of first Phase I clinical trial |
|
Upon completion of first Phase II clinical trial |
|
|
|
|
|
|
$ |
1,000,000 |
|
12 months from completion of the first Phase II clinical trial |
|
Upon first patient treated in a Phase III clinical trial |
|
|
|
|
|
|
$ |
10,000,000 |
|
7 years from the effective date of the agreement |
|
Upon FDA BLA approval |
The
Company has met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing
AL001. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement.
Licensor
was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company
while Licensor remains the owner of any equity securities of the Company.
On
June 10, 2020, the Company obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy
named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer’s and the other
license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to
be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June 10, 2020 and
effective as of November 1, 2019, with the Licensor and the University of South Florida (the “June AL001 License Agreements”).
Under each of the June AL001 License Agreements, a royalty payment of 3% is required on net sales of products developed from the
licensed technology. For the two (2) additional AL001 licenses, in the aggregate, the Company has paid initial license fees of $20,000.
Additionally, under each of the June AL001 License Agreements, the Company is required to pay milestone payments on the due dates to the
Licensor for the license of the technology, as follows:
Additional
AL001 Licenses:
Payment |
|
Due Date |
|
Event |
$ |
50,000 |
|
Upon IND application filing |
|
IND application filing |
|
|
|
|
|
|
$ |
150,000 |
|
12 months from IND filing date |
|
Upon first dosing of patient in a clinical trial |
|
|
|
|
|
|
$ |
400,000 |
|
12 months from first patient dosing |
|
Upon Completion of first clinical trial |
|
|
|
|
|
|
$ |
1,000,000 |
|
36 months from completion of the first Phase II clinical trial |
|
Upon first patient treated in a Phase III clinical trial |
|
|
|
|
|
|
$ |
8,000,000 |
|
8 years from the effective date of the agreement |
|
First commercial sale |
The
Company is authorized to issue 10,000,000 shares of Preferred Stock $0.0001 par value. The Board has designated 1,360,000 shares as the
Series A Preferred Shares. The rights, preferences, privileges and restrictions on the remaining authorized 8,640,000 shares of Preferred
Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares,
as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares.
Series A Preferred Shares
As of July 31, 2022, there
were no Series A Preferred Shares or any other shares of Preferred Stock issued or outstanding.
Common Stock
On April 30, 2019, the Company
and ALSF entered into a SPA for the purchase of 10,000,000 shares of Common Stock for a total purchase price of $15,000,000, or $1.50
per share with 5,000,000 warrants with a 5-year life and an exercise price of $3.00 per share and vesting upon issuance. The total purchase
price of $15,000,000 was in the form of a non-interest bearing note receivable with a 12-month term from ALSF, a related party. The note
is secured by a pledge of the purchased shares. Pursuant to the SPA, ALSF is entitled to full ratchet anti-dilution protection, most-favored
nation status, denying the Company the right to enter into a variable rate transaction absent its consent, a right to participate in any
future financing the Company may consummate and to have all the shares of Common Stock to which it is entitled under the SPA registered
under the Securities Act within 180 days of the final closing of the IPO. In May 2021, the term of the note receivable was extended to
December 31, 2023. The note is secured by a pledge of the purchased shares.
In March 2021, the Company
entered into a securities purchase agreement with DPL pursuant to which the Company agreed to sell an aggregate of 6,666,667 shares of
Common Stock for an aggregate of $10 million, or $1.50 per share, which sales will be made in tranches. On March 9, 2021, DPL paid $4
million, less the $1.8 million in prior advances and the surrender for cancellation of a $50,000 convertible promissory note held by BitNile,
for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, DPL (i) purchased an additional
1,333,333 shares of Common Stock upon approval by the FDA of the Company’s IND for its Phase IA clinical trials for AL001 for a
purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials
for AL001 for a purchase price of $4 million. The Company further agreed to issue to DPL warrants to purchase 3,333,333 shares of Common
Stock at an exercise price of $3.00 per share.
Finally, the Company
agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, on April 28, 2022, DPL
will have the right to invest an additional $10
million on the same terms, except that no specific milestones have been determined with respect to the additional $10
million as of the date of this Quarterly Report.
The Company has evaluated
subsequent events through the date the financial statements were issued. The Company has determined that there are no such events that
warrant disclosure or recognition in the condensed financial statements presented herein.